By combining CK2 and AKT inhibitors (CX4945 and MK2206), we demonstrated an additive inhibitory effect on cell viability (MTS assay) but this occurred only in mucin- and mixed-IHCCA, not in CK19-mucin cell cultures, suggesting a particular resistance of CK19 expressing CCA cells to CK2 and AKT inhibition (Fig 2E). This evidence concerns the gene AKT1 and cholangiocarcinoma.